Showing posts with label Feature. Show all posts
Showing posts with label Feature. Show all posts

Monday, April 13, 2009

Integrity and objectivity on trial: Rebuilding confidence

Medical Tribune March 2009 P16

The ongoing fallout from the withdrawal of rofecoxib in 2004 continues to expose the core values of the international research community to debate. In the second of a two part series, David Brill looks at the safeguards being put in place to prevent it from happening again, and finds out how Southeast Asia can play its part in helping to restore the damaged reputation of medical research.


When the integrity of medical science is threatened, “patients, clinicians and researchers are all at risk of harm, and public trust in research is jeopardized,” wrote the editors of the Journal of the American Medical Association in an editorial last year. “Ensuring, maintaining, and strengthening the integrity of medical science must be a priority for everyone,” they concluded. [JAMA 2008; 299(15):1833-1835]

The trigger for this call to action was the publication of two new papers shining yet more light into the uncomfortable darkness surrounding the withdrawal of rofecoxib. With every painful new insight revealed by the ongoing litigation process – these latest revelations alleged the ghostwriting of manuscripts and the questionable presentation of mortality data in key clinical trials – the restoration of this integrity seems an ever-more distant target. [JAMA 2008;299(15):1800-12; JAMA 2008;299(15):1813-7]

The task is one that faces the entire medical profession, but for Professor Jeffrey Drazen, editor-in-chief of the New England Journal of Medicine (NEJM), it has taken on a particularly personal significance. The journal became an unwitting accomplice in the rofecoxib affair when it published the Vioxx Gastrointestinal Outcomes Research (VIGOR) study – later to be tainted for its omission of three late-breaking myocardial infarctions. [N Engl J Med 2000;343:1520-8; N Engl J Med;2005 353:2813-4] The saga, he says, has “changed the rules” for medical journal editors.

The NEJM, for its part, is fighting on several fronts to ensure the objectivity of the research contained within its pages. Along with other major medical publications, the journal now stipulates that clinical trials be registered in an international database – a requirement which prevents the changing of protocols mid-trial and creates an internationally-harmonized norm, Drazen says. The editors have also learned to demand personal accountability for the data, request longer adverse event reporting, and be more aggressive about querying authors when they feel that there are discrepancies, he adds.

Drazen believes, however, that the long-term solution to the rebuilding process lies out of the hands of the journals and at the very heart of medical research training. “People need to understand that you’re not here to make the boss happy – you want to report the truth,” he says. “In all research we need to teach this culture that [focuses on] getting it right, not just getting it published. Publishing papers is a way to gain fame and reputation, but if you publish a lot of papers that are wrong you’ll start off on a high but you’ll crash.”

The damage to the reputation of medical research has perhaps been most keenly felt in the US, but for Southeast Asia the stakes are equally high. As the region continues to promote itself as a biomedical research hub, financial and commercial interests in its countries grow, and the potential for disaster increases. And with the shadow of Dr. Hwang Woo Suk, the discredited South Korean stem cell scientist, still looming large, the need for adequate ethical safeguards in the region is beyond question.

Singapore, for one, appears already to be taking action to ensure the future integrity of its research. Ethics feature prominently in the nation’s Good Clinical Practice (GCP) Guidelines, a cornerstone of all research conducted in the country, and are also moving up the agenda at the Yong Loo Lin School of Medicine, which in September 2006 became the first medical school in Southeast Asia to open a dedicated academic center for biomedical ethics. At the national level, approval for clinical trials must be gained from the Health Sciences Authority, which scrutinizes all proposals before granting the required certificate.

Much of the responsibility for protecting the integrity of research, however, still lies at the doorsteps of the individual centers and their institutional review boards. Professor Fong Kok Yong’s role, as chairman of division research, is to promote and encourage research at Singapore General Hospital (SGH) – just one of several research centers in the country which prides itself on its publication output. He says that he is happy with the ethical safeguards that are presently in place, but stresses that it is an ongoing, “lifelong” process to instill the appropriate values in SGH’s researchers.

“Medical school is a good start but lectures are just laying some of the foundations,” he says, noting that researchers continue to learn from their peers through an informal mentorship network. The hospital has also been strengthening its educational agenda – offering additional courses and seminars which, Fong says, have been received with enthusiasm by researchers. A recently launched 2-day workshop, focusing on the ethics of GCP and involving speakers from both academia and industry, was heavily oversubscribed, he notes. SGH also implemented a “whistleblower” policy in 2007 to help protect the integrity of its research – allowing researchers to report fraudulent activities without fear of reprisals, and enabling an independent investigation to be undertaken.

Fong adds that it is important to maintain a balance where the frontiers of knowledge and technology can continue to be pushed but without sacrificing patient safety in the process. “As in all things in science, to compete is good, but we don’t want people to compete at all costs. At SGH I think there is a balance – we want to emphasize that it’s not so serious that if you don’t publish you will perish,” he says.

Although Southeast Asia has so far been spared the type of incident where patients are put at risk, the research community here must continue to strengthen its defenses, according to Dr. Thiru Thirumoorthy, a former director of the Singapore Medical Association’s Centre for Medical Ethics and Professionalism. He believes that the rofecoxib story should serve as a wake-up call for the rest of the world, and draws attention to the wider ethical issues of conflicts of interest and the relationships between doctors and pharmaceutical companies.

“Of course the pharmaceutical industries are much bigger in the US so they have greater stakes, but this is by no means purely an American condition,” he says. “The lesson to learn is for us not to reach this point. We should have already put up our barriers much earlier.”

Thirumoorthy believes that in Singapore, in general, the relationships between academia and industry are relatively well moderated at present, but notes that in the absence of definitive evidence the community should remain on guard against complacency. “The first question we need to ask is do we have a problem and is it severe enough for us to do something more? At the moment there is no obvious evidence that it has reached a stage of an exploitative nature. There may be incidences that we do not know of but until such time we should continue to work on education and enforcing guidelines to improve the situation.”

Ultimately, however, only time will tell whether the global medical community is doing enough to protect itself, and whether the public’s faith in medical research can ever be fully restored. Despite the profession’s best attempts to tighten its defenses, it may simply be a matter of time until its values are once again left cruelly exposed.

“We’re doing our best to try to keep people honest but I’d be a fool to say that it won’t happen again,” concludes Drazen. We’re protecting against things that happened in the past but somebody will be creative and come up with something new and there’s nothing you can do about it. If someone wants to cheat badly enough, they’ll succeed.”

Professor Jeffrey Drazen was in Singapore as part of the National University Health System’s Distinguished Editors Series.

Darwin’s legacy in the balance: The splendor of the Galapagos Islands

Medical Tribune March 2009 P18
David Brill

The Galapagos Islands are treasured by naturalists the world over for their unrivalled diversity of wildlife and geology. David Brill visits the islands, and reports on the difficult challenges they face.

February 12th saw the world celebrate the life of one of its great scientific heroes. Two hundred years on from the birth of Charles Darwin, and 150 from the publication of his much-celebrated On the Origin of the Species, his theories of natural selection continue to this day to shape our understanding of the world around us and our appreciation of the history of mankind.

The Galapagos Islands, located around 1,000 km to the west of mainland Ecuador, played an integral role in the development of Darwin’s theories. He visited the archipelago in 1835 aboard the HMS Beagle, on its way back to England from a 3-year voyage around the coastlines of South America. An enthusiastic naturalist with a seemingly limitless capacity for taking notes and collecting specimens, it was here that he acquired the data which were to famously mould his thinking on evolution. The different sub-species of finch, each one perfectly adapted to its niche on the respective islands, has become perhaps the best-cited example of his inspiration.

To visit the Galapagos Islands today is to grapple with a difficult ethical dilemma. The national park authorities depend on the income from tourism to enact the conservation projects that seek to preserve the islands’ unique ecosystems, yet it is the influx of tourists which hastens their very demise. The annual number of visitors rose from 68,856 in 2000 to 108,436 in 2004 – pairing a substantial rise in income with an equivalent threat from pollution and the introduction of non-native species. Andrew Marr, president of the Galapagos Conservation Trust (GCT), warned recently that development needs to be brought under control, and suggested that tourists be restricted to one visit per lifetime. Marr himself, a well known British journalist and commentator, has pledged never to return despite falling in love with the islands on a visit in 2002 and taking up the GCT presidency in 2006.

For those who do exercise their right to make this literal once-in-a-lifetime trip, it is easy to see why Marr feels so strongly about the preservation of the Galapagos Islands. The beauty and diversity are every bit as spectacular as promised, and can scarcely be captured in words or photographs. There can be few spots in the world where you can watch a mother hawk teaching her young to swoop for marine iguanas, which scurry for cover in the cracks of a scarred volcanic landscape. With sea lions sunbathing on bright white sand to your left, albatrosses circling a haunted-looking scrub of a forest to your right, and giant turtles peeking their heads out from the shining blue ocean ahead of you, the list of possible locations is surely shortened to one.

The Galapagos Islands sit on a tectonic conveyor belt above a submarine volcanic hotspot. As new cone-shaped islands rise up from the seabed, they begin to move slowly away from the lava source, becoming cool and inactive as they are carried east and eventually worn down by erosion. At a pace of 75 mm per year this is a slow process: Espaňola, the oldest of the 13 main islands, is estimated to be around 4 million years old while Fernandina is the youngest at under a million years and remains volcanically active to this day.

It is this diversity of geology that has given rise to the islands’ astonishing range of wildlife, fostering the evolution of several species which do not exist anywhere else in the world. While Fernandina sits barren and lifeless, its red rocks resembling a Martian landscape, Espaňola is green and verdant and contains many of the natives endemic to the Galapagos. In the middle sits Santa Cruz, the second largest of the islands and home to Puerto Ayora, the major population center of the islands. Santa Cruz is also the residence of Lonesome George – the world’s last surviving giant Pinta tortoise and the most famous citizen of the Galapagos (pictured). Despite countless attempts to encourage him to bear offspring he continues to live out his days as a bachelor at the Charles Darwin Research Station, apparently oblivious to the demise of his species and the iconic status he has gained among environmentalists.

There are signs that tourism in the Galapagos Islands is slowing in the current economic climate. Some of the cruise liners have received unusually high numbers of cancellations and are down-scaling their itineraries for this year. It remains to be seen how the islands will cope with this drop in the income which has become such a double-edged lifeline, and whether the unique beauty of the Galapagos will benefit or suffer from this downturn. As long as tourism can be appropriately managed and regulated, however, there is little doubt that the Galapagos Islands will remain one of the world’s greatest destinations – as inspiring to travelers today as they were to Darwin himself.

Monday, March 30, 2009

Integrity and objectivity on trial: The enduring legacy of rofecoxib

Medical Tribune February 2009 SFVI
David Brill

The events surrounding the withdrawal of rofecoxib shattered the widely held assumption that medical research serves to protect the public interest. In the first of a two-part series, Medical Tribune’s David Brill speaks exclusively to two of the central characters in the story of the key rofecoxib trial to find out what happened and what they have learned from the affair.

On December 29th 2005, the public’s fragile faith in medical research took another near-fatal blow. The withdrawal of the multi-billion dollar ‘blockbuster’ arthritis drug rofecoxib (Vioxx) the year before had been testing enough, but the latest revelation that safety data had been concealed in a key clinical trial of the drug was the final straw. The notions of objectivity and integrity that had lain at the very heart of research were exposed to an intense and damning scrutiny that continues to dominate both the academic and lay press to this day.

Rofecoxib, a selective cyclooxygenase-2 inhibitor, was voluntarily withdrawn in September 2004 by its manufacturers Merck & Co., which announced that ongoing research had shown definitively that the drug raised the risk of cardiovascular events. The news was shocking enough for the academic community – concerns had been repeatedly expressed but had largely gone unheeded by the manufacturers – but for the public the sheer magnitude of the decision was devastating. The drug had been on sale for more than 5 years in over 80 countries – leaving millions of people exposed to potentially avoidable heart attacks and strokes.

The affair left a profound legacy for the entire medical profession but for the members of the International Committee of Medical Journal Editors (ICMJE), it was a particularly bitter pill to swallow. Three years before the announcement they had warned in an editorial that the “precious objectivity” of medical research was under threat from the growing involvement of corporate sponsors in clinical trials which, they said, was allowing companies to increasingly dictate their own terms regarding the design, interpretation and publication of clinical trials. The gravity of the warning was clear but the timing of publication – September 10th 2001 – proved to be unfortunate when events in New York the following day pushed the discussion of medical ethics firmly to the bottom of the news agenda.

Objectivity and integrity are core values for all of the medical journals but for none is the weight of expectation greater than for the New England Journal of Medicine (NEJM). The journal – perceived by many researchers as the ultimate outlet in which to publish their work – has the highest impact factor of any medical journal and bestows upon its papers an inherent authority and prestige that only one or two other publications could claim to match. In 2007 alone the NEJM received some 6,000 original research papers, of which just 5 percent were published.

It was to the consternation of its editors, therefore, that the NEJM was to find itself sucked into the post-rofecoxib storm. As the legal process continued, attention turned to its November 2000 publication of the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial, comparing the gastrointestinal toxicity of rofecoxib with naproxen in 8,076 rheumatoid arthritis patients. [23;343(21):1520-8] The plot had already begun to thicken in 2001 when an updated data set from the trial was presented to the US FDA, showing that three extra myocardial infarctions (MIs) in the rofecoxib group had occurred shortly after the cut-off point for the reporting of adverse events – results that, had they been included in the VIGOR analysis, would have increased the relative risk of MI from 4.25 to 5.00 for patients taking rofecoxib.

The NEJM editors were reassured that these were “late data” which had only been discovered after publication, but in November 2005 they learned that all was not as it had seemed. The extra MIs had, it emerged, been known about almost 5 months before the publication of VIGOR, giving the authors ample opportunity to include them in the 2000 paper. The NEJM announced the news by publishing an “Expression of Concern” on December 29th 2005, highlighting the “misleading conclusion” of the trial and questioning the integrity of its data. [29;353(26):2813-4]

For Professor Jeffrey Drazen, the journal’s editor-in-chief, the lesson of the story is clear. “We used to assume that everybody understood the rules. Now we no longer expect that people will play by them,” he explained on a recent visit to Singapore.

“When we discovered the extra events the authors said ‘well, we don’t know about this’. And in fact they didn’t.” It was hidden from them, says Drazen. “The violation of ethics, in my opinion, was not putting the material out in the open. So in retrospect, when it became clear that there was a discrepancy between what was in our pages and the data set sent to the FDA, we should have been more aggressive about querying the authors.”

The NEJM now takes a more direct interest in adverse event reporting when it comes to assessing the design of trials, according to Drazen. An unusual situation had arisen in VIGOR whereby the closing date for reporting GI bleeds – the study’s primary endpoint – was extended beyond the closure of the adverse event database. The trial continued for several weeks, but the additional cardiovascular events that occurred during this window were not included.

“They designed the trial in a sneaky way and never told anybody about it. Now we’re smart enough to ask about this. We want adverse event reporting up to the day of acceptance, not as of some prespecified day.”

Demanding accountability for the data is perhaps the most important lesson that the NEJM has learned from rofecoxib but now, Drazen says, they have “turned it around” by attaching a stronger sense of responsibility to research authorship. A study printed in the journal today may appear overtly similar to one published pre-rofecoxib, but a closer look at the methods section now reveals the key statement: “All authors had full access to the data and vouch for the accuracy and completeness of the data and the analyses.”

“The most important thing you have as an academic researcher is your reputation,” explains Drazen. “If you want to maintain your reputation you have to go to the company and say ‘I can’t put my name on this paper until I’m sure that the data I’m reporting are accurate and complete. I need to be sure that it’s my paper.’ Had we had such a statement from the authors we’d have been able to go back and tell them that they had committed perjury but we couldn’t do that.”

For Professor Richard Day, one of the academic authors of the VIGOR study, this is a lesson which had to be learned the hard way. The years that followed the NEJM’s Expression of Concern were difficult and distressing for him. Not only had his high hopes for rofecoxib been destroyed with the withdrawal of the drug, but now his name and those of his co-authors had been dragged down into the realms of scandal.

“It was a challenging time – there were lawyers engaged all over the place to try to put forward the positions of the various parties and it was all pretty unpleasant. I think we got pretty severely beaten up from all sides,” he says.

Day, a professor of clinical pharmacology at the University of New South Wales in Sydney, Australia, confirms Drazen’s assessment that the academic investigators were kept in the dark about the extra adverse events in VIGOR and feels that much of the “angst and uproar” could have been avoided had these data been discussed with them. He stands firmly behind the study itself, however, feeling that the issue of the extra MIs has been allowed to overshadow what was the largest trial of its kind and an exciting opportunity to tackle the huge problem of gastrointestinal bleeds.

“In my view it’s one of the best studies ever done in the field of rheumatoid arthritis. It has not been recognized for its quality because of this one issue. It’s an important issue, but it’s ruined it in lots of ways,” he says.

It was a strange and ultimately poor decision not to include the extra events, according to Day, but he notes that from a purist’s perspective it was technically correct since the prespecified trial protocol had demanded that they be excluded. The contentious extension of the GI events window was at the request of the academic authors, he adds, noting that it was an endpoint-driven study and that the researchers had simply wanted to accrue as much data as possible about the benefits of rofecoxib. Why the adverse events window was not also extended accordingly he does not know.

The complete story of rofecoxib and VIGOR may never be revealed but for now the scar on the public consciousness endures. Perhaps surprisingly, however, Day feels that despite the “collateral damage” suffered along the way, the long-term legacy of the affair may ultimately help to rebuild the integrity which it once destroyed.

“Clearly the light’s being shone more and more on this interaction between the clinical world and drug companies and that’s a good thing,” he concludes. “I’m sure there’ll be more problems but I think with every one of them we learn, tighten up and try to head them off so that in future we can believe what we see, read and hear, and feel that it represents a proper treatment of data and opinions which is independent and addresses conflicts properly.”

An edited version of this article appeared in Medical Tribune.

Dr. Jeffrey Drazen was in Singapore as part of the National University Health System’s Distinguished Editors Series.

Next month: David Brill looks at how the integrity of medical research can be restored through the lessons learned from rofecoxib.

Sunday, March 15, 2009

The meteoric rise of HIV

Healthy Times December 2008
David Brill (aka David Wise)

December 1 is World Aids Day. To mark the event medical journalist David Wise looks at the humble origins of this global killer and its journey from an isolated outbreak to a worldwide pandemic.

Léopoldville may not be a familiar name to many, yet the city played host to one of the defining events of mankind’s recent history. The former Belgian colonial capital – now known as Kinshasa, Democratic Republic of the Congo – is thought to be the birthplace of HIV, the virus responsible for the AIDS pandemic which is currently affecting over 33 million people worldwide.

The precise origins of HIV remain a mystery but new research allows scientists to paint a more detailed picture than ever before. They now believe that the virus first reached humans in Léopoldville around 100 years ago, where it found a foothold among the booming population of the newly-founded city.

It is likely that HIV spread slowly at first, experts say, while the fact that symptoms differ widely between individuals may have prevented it from being recognized for many years. It was not until 1981 that French scientists Françoise Barré-Sinoussi and Luc Montagnier formally identified the virus – a discovery that was honored this year with the award of the Nobel Prize for medicine.

The true beginning of the story, however, begins not with humans but with our primate cousins. Today there are several different types of HIV, each of which may have its own tale to tell, but the particular strain responsible for the current pandemic seems to have evolved from a virus which naturally infects chimpanzees. In 2006 researchers announced that they had found this HIV forefather – the Simian Immunodeficiency Virus (SIV) – among wild chimps living in southeast Cameroon.

Most scientists accept that SIV became HIV, but how it first crossed the species barrier is largely a matter for speculation, according to Professor Robin Weiss, an HIV expert from University College London, UK.

“The most likely explanation is that it began with the butchering of apes,” he explains. “There was blood and splintered bones and goodness knows what lying around, and then the virus got transferred into small cuts or abrasions on the skin. If you wanted to be lurid you could raise a King Kong scenario of sex with a great ape but I think that’s a bit sensational myself.”

The first known case of HIV comes from a preserved tissue specimen dating back to 1959, which was found in the archives at the University of Kinshasa. In 2000, Betty Korber and her team at the Los Alamos National Laboratory, US, published an important research paper analyzing the genetic sequence of this virus. Their calculations, they said, suggested that the virus had likely been born around 1931 – back when Kinshasa was still known as Léopoldville.

But this information begged an important question which has only recently been answered: how did the slaughtering of chimps in southeastern Cameroon lead to the infection of humans in Léopoldville some 700km away?

The answer was provided in October of this year when Michael Worobey and his colleagues from the University of Arizona, writing in the journal Nature, announced that they had found another early HIV specimen lurking in the archives at Kinshasa. The tissue sample – a lymph node taken from an adult woman – had been fixed in preservative back in 1960.

This discovery enabled the team to compare the virus with Korber’s specimen from 1959. By looking at genetic differences between the two samples and tracing their family trees backwards, they established that the viruses must have shared a common ancestor between 1884 and 1924. Their best estimate puts the birth of HIV at 1908 – some 23 years earlier than previously thought.

Worobey’s team went one step further and placed their genetic studies alongside demographic data on the growth of cities in west-central Africa. They found that their estimate of 1908 coincided with a period of population boom in Léopoldville, suggesting that growth of the city provided the necessary kick-start for HIV to spread. Before 1900, there was not one settlement in the area with more than 10,000 people, but by 1910 Léopoldville had established itself as the region’s major city.

As the colonial outpost grew, so it continued to flourish as an administrative and trading center. With transportation at the time largely restricted to boats, Léopoldville found itself ideally situated on the Congo River – the final destination of many of the tributaries that run through the forests of Cameroon. The identity of the person that first contracted SIV may remain a mystery, but their arrival in the city now seems the likely trigger for the modern-day AIDS pandemic.

This newfound understanding of where HIV came from can provide important insights into the evolution of future pandemics, according to Weiss.

“These examples of particular viruses help to inform our general thinking about the origins of infections that come from animals. And for sure we’ve haven’t seen the last one – there’ll be some other disease like SARS or something that we haven’t even thought about today,” he says.
“And looking back at HIV in its very humble, small beginnings… who would have guessed that this would turn out to be the major killer at the end of the 20th century?”

Tuesday, February 10, 2009

Staring disaster in the face

Medical Tribune October 2008 P11
David Brill SFXV

Dr. Arif Tyebally is a veteran of disaster relief missions in South East Asia. He spoke to Medical Tribune’s David Brill about dealing with tsunamis, earthquakes and cyclones.

December 26 2004 was a day that
changed the lives of countless people.
As a 9.3-Richter earthquake
shook the ocean floor off the coast of Sumatra,
the tsunami that resulted at the surface
killed more than 200,000 and left some half a
million homeless.
Dr. Arif Tyebally witnessed the devastation
first hand. Arriving in Aceh, Indonesia,
as part of the emergency relief effort, he saw
homes destroyed, families separated and
people living through hardships he had never
imagined possible.
“To this day I can’t think of anything that
could be worse than the tsunami,” he says.
“It was unbelievable. Thousands of homes
just flattened. Nothing can recreate it, and
nobody can describe how bad it really was.
I don’t think anyone could be prepared for
what we saw.”
On a regular day, Tyebally, 33, is a pediatrician
at KK Women’s and Children’s Hospital
in Singapore. He decided to volunteer
for the mission to Aceh when he saw the extent
of the destruction on television. While
millions donated their money, he felt that offering
his medical expertise was a better way
to help.
On arrival in Aceh, the Singapore team
lived in a camp for internally displaced
people, where they set up and ran a general
clinic. Being part of the second wave of relief
teams, there were few acute injuries from the
tsunami itself, and they treated mainly postdisaster
complications such as gastroenteritis
and respiratory and skin infections. With
local pediatric facilities severely stretched –
one local hospital with facilities having been
completely destroyed and another badly
flooded – Tyebally helped to run a makeshift
pediatric department in a nearby military
hospital.
In spite of the devastation all around
them, the residents of the camp showed a resilience
which inspired Tyebally.
“People would go back to where their
homes used to be to search amongst the
rubble, and if they could find something like
a sewing machine they’d take that back and
start to work from the camp. And the children
still went to school, even if they’d lost
their parents. I’m sure they must have been
going through really hard times, but it was
good to see that despite the situation that
they were in they were all trying to get back
to their daily lives,” he says.
Tyebally spent 10 operational days in
Aceh, treating some 70 patients each day. For
many, however, the tsunami had left wounds
that he was powerless to heal. He recalls the
thousands of photos of missing children that
lined the walls, and the haunting memory of
one lady who spent weeks going from hospital
to hospital looking for her child, long
after the waters had subsided.
“You can’t really help someone like that,”
he says. “You just have to talk to them. They
probably know that there isn’t much hope,
but for a mother any hope is still hope. It’s
very sad to see things like that happening.”
With some of these memories still troubling
him to this day, you could have forgiven
Tyebally for shying away the next time a
natural disaster struck in Asia. Yet in October
2005 he found himself among the first official
medical teams to arrive in Muzaffarabad,
Pakistan, following a 7.6-Richter earthquake
which left some 80,000 people dead.
The Singapore team set up a hospital –
again within a tented camp – comprising an
emergency room, wards and an operating
theater. Unlike in Aceh, however, the team
was treating mostly acute cases such as fractures
and open wounds. Some patients, he
says, had walked for 5 days with fractured
hips in order to receive treatment.
The conditions encountered in Pakistan
were also a challenge for the relief teams.
Aftershocks from the earthquake were common,
while sleeping in tents in an inaccessible
mountainous region with winter approaching
ensured that living conditions
were far from luxury.
For Tyebally, who speaks Bahasa Indonesia,
the language barrier in Pakistan was another
new problem which he had not faced
in Aceh. He soon realized the need to work
closely alongside local volunteers, many of
whom had given up paid jobs to come and
help out at the disaster zone. He was touched
by how helpful the people were – both in assisting
with the logistics of the team’s medical
operations and acting as interpreters for
the patients and local medical staff.
With two disaster relief missions under
his belt, Tyebally was elevated to Singapore’s
team leader when Cyclone Nargis struck
Myanmar at the beginning of May this year.
With much of the world denied access to the
country, Tyebally and his team found themselves
operating for the first time without the
coordination and resources of the UN.
Undeterred, the 23-man team managed
to treat nearly 5,000 patients in just 2 weeks,
operating from their base in Twan Te – a
town around an hour’s drive southwest of
Yangon. They worked out of a local hospital
but also set up mobile clinics and travelled
by boat to deliver aid to the region’s more
remote corners.
Two weeks had passed between the advent
of the cyclone and the arrival of international
aid, and the team mostly encountered
a similar post-disaster caseload to that seen
in Aceh. There were also many patients with
untreated chronic diseases such as hypertension
and diabetes who took the opportunity
to seek medical attention from the doctors.
Myanmar also presented Tyebally with
one case that he will never forget – a young
girl with ascariasis, a parasitic infection in
which worms mature in the intestine and
migrate up the respiratory tract.
“The family didn’t seem very upset
or perturbed by it. In fact she came in for
something else and oh, by the way, there are
worms coming out of her mouth,” he says.
Everywhere Tyebally has been he has
been struck by the gratitude that the people
have shown him. Sometimes he wishes he
could do more, he says, but adds that even
when nothing can be done the patients are
often glad of the sense of closure that comes
from knowing their fate.
He shrugs off the notion that his work is
heroic, describing it simply as a form of charity
work like any other.
“It takes so little for us to give to make a
big difference to the lives of the people. Not
many people want to go on such missions
because there are dangers, but I think that
the benefits – the sense of satisfaction and
the fact that you can help people – outweigh
these.”
His experiences, he adds, have helped
him not just in a professional context but also
to grow and develop as a person.
“You gain as much from the patients as
they gain from you. You see how resilient
they are in the face of suffering, and how
they can turn their lives around and get back
to their normal routines despite all that has
happened. It really makes you appreciate
what you have.”
Tyebally, it seems, is just one of those
whose lives were forever changed by that
fateful day in 2004. And next time disaster
strikes, he says, he’ll be ready to go where
the people need him.

Monday, February 9, 2009

The David Beckham of science? Get real Dad



Medical Tribune August 2008 P16 - 17

Winning the Nobel Prize earned Sir Paul Nurse the respect of doctors, scientists
and reporters the world over. He told Medical Tribune’s David Brill what it
takes to become a Laureate, and why his daughter was less convinced.





There can be few achievements
in life that surpass
being knighted. But for a
Nobel-winning scientist there’s an
obvious trump card.
Sir Paul Nurse is one of the
privileged few who can say which
feels better. Driven by a passion
for wanting to learn how the natural
world worked, his career as
a biologist led to the “very pleasant
shock” of royal recognition in
1999.
But while his father was more
excited about the knighthood,
Nurse himself doesn’t hesitate
to name the 2001 Nobel Prize for
Physiology or Medicine as his
greatest success. Recognition of a
different kind was to follow, with
The Sun newspaper in his native
UK dubbing him “the David Beckham
of science” – an acknowledgment
of his failure to conform to
public stereotypes of white coats
and safety spectacles.
Seven years later the award
has finally sunk in, he says, but
the rapid elevation of status that
accompanies the Nobel Prize still
takes some getting used to.
“You’re really no different from
what you were before but it’s simply
that people take more notice
of you. Suddenly you become the
expert on almost anything, and not
just science. This can be slightly
embarrassing, because every time
you open your mouth you think
that someone’s going to write it
down.”
Nurse received the Nobel Prize
for his work on the molecular regulation
of the cell cycle – a research
interest which began in the 70s,
when his studies of yeast led him
to identify the cdc2 gene, which
plays an important role in controlling
the progression between the
stages of cell division. In 1987 he
discovered the human equivalent
– the CDK1 gene which encodes a
cyclin dependent kinase.
At the time of the award he
was director general of the Imperial
Cancer Research Fund (ICRF),
which later became part of the
charity Cancer Research UK. He
shared the Nobel Prize with Tim
Hunt, a British biochemist, and
Leland H. Hartwell, an American
scientist who is now director of the
Fred Hutchinson Cancer Research
Center in Seattle, US.
There are certain prerequisites
to winning the award, Nurse says,
noting that hopefuls need to be
“reasonably bright, but not necessarily
super-bright, and a reasonably
good scientist and experimentalist.”
Beyond the basics, however,
the first factor he identifies is circumstance.
“It does require a certain combination
of being in the right place
at the right time, which singles out
certain advances as being iconic,
and which can be clearly identified
with a few individuals. There are
many other advances – sequencing
the human genome is one which
everybody will talk about – but it’s
very difficult to identify the person
or limited group of people who are
involved in that.”
The second key to becoming
a Nobel laureate, he says, is to be
seen to be doing something that
other people aren’t. In his case a
long-standing interest in cell division
led him to begin his research
while the competition was limited,
and by the time others recognized
the importance of the field his reputation
within it was already established.
Author of over 200 scientific
papers – many of them in Nature,
Science and Cell – Nurse also emphasizes
the importance of being
able to write clearly and insightfully.
“Often people write papers
which can never be wrong because
they just agree with everything
that’s out there and then they’re
very muddy. You’ve got to stick
your neck out a bit at a stage where
you’re prepared to be wrong… if
you end up being right, then that’s
more clearly identifiable than if
you write something which says
‘it could be this or it could be that,’
because that lacks clarity.”
Nurse grew up in Wembley in
north-west London, going on to
study at the Universities of Birmingham
and East Anglia before
joining the ICRF in 1984. After a
5-year stint as chair of the department
of microbiology at The University
of Oxford, he returned to
the ICRF as scientific director in
1993 and was appointed director
general in 1996.
In 2003 he left the UK to become
president of Rockefeller
University in New York, a position
he still holds today. He is
also a regular visitor to Singapore,
where he chairs the scientific advisory
board of the Temasek Life
Sciences Laboratory.
Becoming a Nobel laureate is
like having another job in itself,
Nurse says, admitting that the many
extra requests on his time can be difficult
to manage. But describing his
profession as “a privilege,” it’s clear
that he wouldn’t want it any other
way. And should he ever get carried
away with his new-found fame, he
need only speak to his family to be
brought back down to earth.
“I’ve got two daughters – one’s
a scientist, the other’s a TV producer
and interviewer for soccer
who has interviewed David Beckham.
And when I pointed out The
Sun headline to her she just said
‘Get real Dad. You are not David
Beckham.’”











Unraveling complexities in cancer research


What has been the greatest
breakthrough in cancer
research in the past 10 years?
Identifying which genes become
altered in cancer, and in
which combinations, has been
a major advance. We now know
that there are 300 to 400 genes that
are important, and knowing those
does two things: firstly, it helps us
understand this immensely complicated
disease much better, and
secondly it gives us new targets
to think about for both diagnosis
and therapy.
What are the greatest
challenges facing the field in
the next 10 years?
The greatest challenge is dealing
with the wide range of changes
that can bring about the cancerous
state, and producing a rational
therapeutic response to all of
those different changes. Given that
complexity, it’s not going to be like
infectious disease research, for example,
where penicillin had a major
impact. Cancer’s going to be a
more brick-in-the-wall approach
– it’s going to gradually get better.
Cancer and breakthrough don’t go
together.
What advice would you give
to doctors who want to make
a career for themselves in
research?
There is one crucial factor: they
have to be driven by a passion for
wanting to know. Doing research
is very demanding and often not
rewarding. People think that it is,
but real success is very difficult to
achieve. You have to have a real
passion to cope with the fact that
the recognition and success that
come through are limited.
Who are your scientific
heroes?
Well I’m a biologist so I’m going
to be traditional and say Darwin
as my all-time hero. I can’t
help it. And he’s English, too. In
more recent years I think I’ve got
to say Francis Crick and maybe
Sydney Brenner, both of whom I
knew.
Several countries in the
Asia Pacific region are
becoming up-and-coming
centers for research. What
advice do you have for the
scientific community in these
countries at this stage?
The difficult trick to balance is
that you need to support science
across a fairly wide base. If you
only support research which is just
before application, which is the
tendency to do if you are looking
for commercial return, you really
are not investing in the future. And
if you only support basic research
which is looking for the future then
you don’t get the immediate commercial
return. What is required is
a broad-based approach that covers
the whole timeline.
What’s the best memory
from your childhood in
London?
I think my best memory really,
scientifically at least, was
being able to access all the great
museums in London. I happened
to be a bit of a museum kid so I
thought they were fantastic. I
think it inspired me, certainly in
part.


Thursday, February 5, 2009

Doctors sacrifice honoraria in quest for objectivity



Medical Tribune July 2008 P12-13
David Brill

Feeling their integrity questioned, some doctors are beginning to reject money
from the pharmaceutical industry. David Brill reports.

Professor Kelly Brownell
was once offered US$50,000
to join the advisory board
of a pharmaceutical company. He
turned it down and “feels good
about the decision.”
Brownell, director of the Rudd
Center for Food Policy and Obesity
at Yale, is one of several highprofile
US academics who have decided
to stop taking any payments
from the industry. He gradually
settled on the decision around 10
years ago, having begun to question
the influence that financial
reimbursement was having on his
professional judgment.
“Scientists pride themselves
on objectivity as their cardinal virtue,
but it’s remarkable how nonobjective
scientists can be when
conflicts of interest are involved,”
he said, citing the literature published
around the subject as the
main factor in his decision.
“The studies suggest that
when industry pays for research
or pays people as consultants they
get something in return. And in
addition, the studies show that
industry-funded science typically
finds results favorable to the industry,”
said Brownell. In his own
experience, he added, he felt “a
natural tendency to want to help
the companies.”
“The money really comes in a
lot of different forms but the two
main ones are funding for one’s research,
and then the other is money
that you get as an individual,” he
explained.
“People become reliant on
these things. For some the money
can be considerable, and it pushes
them up the social and economic
ladder. And for a lot of people
they don’t want to go down a rung
or two.”
Brownell’s move has recently
been followed by two doctors at
Harvard – Peter Libby, the chief of
cardiovascular medicine, and Eric
Winer, the director of the Breast
Oncology Center at the Dana-Farber
Cancer Institute. How many
more doctors in the US will follow
their lead remains to be seen.
Conflicts of interest are presently
a hot topic in the US. A recent
high-profile editorial in the
New England Journal of Medicine
called for greater transparency in
the declaration of funding sources,
concluding that: “The public’s
trust in biomedical research depends
on it.” [N Engl J Med 2008
Apr 24;358(17):1850-1] The murky
nature of the relationships between
doctors and pharmaceutical
companies has also prompted
two senators – Chuck Grassley of
Iowa and Herb Kohl of Wisconsin – to propose new legislation
that would make it mandatory
for pharmaceutical companies to
publicly declare how much money
is given to doctors. The proposal,
known as the Physician Payments
Sunshine Act, has received the
public backing of the Association
of American Medical Colleges,
and was also recently endorsed by
Eli Lily.
In Southeast Asia, doctors are
largely governed by guidelines
and codes of ethics issued by the
various medical associations, and
these issues have yet to reach the
mainstream legal agenda. Dr. Ravindran
Jegasothy, former chairman
of the ethics committee at the
Malaysian Medical Association,
believes nonetheless that it remains
very important to educate
medical professionals about how
to handle their relationships with
the industry. He called the decision
by Brownell, Libby and Winer to
distance themselves financially a
“commendable move” in drawing
attention to some of the issues at
hand.
“It sets people thinking: ‘where
is it that we should draw the line?’”
he said. “My personal view is that
if possible, doctors should not be
sponsored by drug companies. I
feel there is always an ethical dilemma
when a pharmaceutical
company sponsors you.
“Senior people should be role
models in how they conduct their
relationships,” explained Jegasothy,
who is also head of the department
of obstetrics and gynecology
at Hospital Kuala Lumpur.
“I feel that an individual who’s
in a leadership position should as
far as possible diverge himself
from the pharmaceutical industry
… In some cases, in our country
we have had bad examples being
set by senior people taking part in
private excursions or golf tournaments
and so on, which you hear
about being sponsored by pharmaceutical
companies. I think that
does not set a good example for
the juniors.”
Jegasothy would encourage
more doctors take a similar stance
to Brownell. Not everyone, however,
is quite so supportive of the
move.
“I think the action in this case
is a bit extreme, quite frankly,” said
Professor Brian Tomlinson, who is
head of clinical pharmacology at
the Chinese University of Hong
Kong. “I think it’s a sort of noble
idea but in practice it’s not easy for
everyone to do that. If everyone
did it the whole progress of clinical
and medical research would grind
to a halt.
“It just isn’t viable for the majority
of doctors doing clinical
research, especially within Asia.
There isn’t that much funding
readily available and if you want
to do any substantial research it’s
necessary to collaborate with the
industry.”
As both a clinician and an academic
researcher, Tomlinson is
used to dealing with patients while
also liaising with pharmaceutical
companies over the development
of clinical trials. He feels that doctors
should keep a balanced view
and avoid aligning themselves with
any one company more than the
others, but should not be encouraged
to renounce pharmaceutical
money entirely. And if they have
to give up their time to advise, he
says, it is reasonable to expect payment
for it.
In Singapore, the academic
research community is not in the
same sort of quandary as Brownell
and his colleagues, according to
Dr. Thiru Thirumoorthy, a former
director of the Singapore Medical
Association’s Centre for Medical
Ethics and Professionalism. Fewer
phase I and II trials are conducted
in Asia than in the US and Europe
so it’s less of a problem at present,
he said.
Thirumoorthy warned, however,
that conflicts of interest will
inevitably arise as more research
is done in the region. He believes
that ethics committees should be
given greater financial support
and resources in order to monitor
research closely and avoid the situation
where doctors feel the need
to distance themselves from the industry,
as their counterparts in the
US have done.
“The lesson to learn is for us
not to reach this point. If you don’t
moderate, beginning early, and if
we don’t have the infrastructure
then we will end up like this,” he
said.
Brownell has his own suggestions
for limiting the potential for
future conflicts of interest involving
doctors and pharmaceutical
companies.
“The problem is pretty obvious.
If an industry does research
on their own products they have
a strong interest in positive outcomes.
One solution would be for
the industry to take some of the
money they’re spending on these
studies, pool it, and let some objective
outside group commission the
study,” he said.
Acknowledging that it could
be harder for more junior doctors
to say no to pharmaceutical sponsorship,
he added that: “The fact
that young people are vulnerable
to the money because they need it
speaks to the sad state of government
funding for research.”
Brownell agreed with Jegasothy’s
point that senior academics
should act as role models for
younger doctors but, not wishing
to sound as though he was
preaching, was reluctant to directly
encourage others to follow his
example.
“I did it because of my own
principles but if it serves as a model
for others then so be it.”